🔧 The lab can produce varied peptide types, improving project timelines significantly.
📈 Automation in Drug Metabolism and Pharmacokinetics boosts efficiency, cutting turnaround times by 40% and tripling sample handling.
💡 This investment targets better scalability and data quality for therapeutic innovation.
Introduction:
The article discusses the recent advancements made by Syngene International, a contract research, development and manufacturing organization (CRDMO), in accelerating its drug discovery and development services. The company’s investment in a dedicated peptide laboratory and advanced automation set to optimize its workflows is the primary focus of the narrative.
- Syngene International has invested in a dedicated peptide laboratory located in Bengaluru to enhance its drug development capabilities.
- The laboratory is equipped to produce various peptide types, including linear and cyclic peptides, and can scale production up to 800 millimoles.
- Advanced automation has been integrated into the laboratory and DMPK (Drug Metabolism and Pharmacokinetics) workflows to enhance efficiency and data quality.
- The automation includes high-throughput systems which have significantly reduced sample preparation time and improved cost efficiency.
- This strategic move aims to streamline therapeutic innovation by combining automation with scientific expertise, enabling faster project turnaround and better service to clients.
Conclusion:
Syngene International’s establishment of a specialized peptide laboratory and the integration of advanced automation into its workflows signify a substantial step towards enhancing drug development efficiency. This investment not only aims to improve operational productivity but also sets the stage for future innovations in therapeutic research, potentially benefiting both the organization and its clientele.
